State of Israel
|
Not Applicable
|
(State or other jurisdiction of
incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
Gary Emmanuel, Esq.
Greenberg Traurig LLP
One Vanderbilt Avenue
New York, NY 10017
Tel: 212-801-9200
|
Adam D. Janoff, Esq.
General Counsel, Head of Compliance & Corporate Secretary
77 Fourth Avenue
Waltham, MA 02451
Tel: 617-859-6409
|
Sharon Rosen, Adv.
FISCHER (FBC & Co.)
146 Menachem Begin Street
Tel Aviv 6492103, Israel
Tel: +972 -3-6944111
|
Large accelerated filer
|
☐
|
|
Accelerated filer
|
☒
|
Non-accelerated filer
|
☐
|
|
Smaller reporting company
|
☐
|
|
Emerging growth company
|
☐
|
|
•
|
our Annual Report on Form 20-F for the year ended December 31,
2022, filed with the SEC on March 22, 2023
|
|
|
|
|
•
|
our Reports on Form 6-K filed with the SEC on January 4, 2023,
March 6, 2023, April
17, 2023, April 25, 2023, May 24, 2023, June 23,
2023, July 17, 2023, August 8, 2023, August
30, 2023, August 30, 2023, September 11, 2023, September
28, 2023, October 12, 2023, November 20, 2023, December
12, 2023 and December 21, 2023 (in each case, to the extent expressly incorporated by reference into our effective
registration statements filed by us under the Securities Act); and
|
|
|
|
|
•
|
the description of our ordinary shares contained in Exhibit 2.2 to our Annual
Report on Form 20-F for the year ended December 31, 2022, filed with the SEC on March 22, 2023, including any amendment or report filed with the SEC for the purpose of updating such description.
|
|
BioLineRx Ltd.
2 HaMa’ayan Street
Modi’in 7177871, Israel
Attention: Corporate Secretary
Tel.: +972-8-642-9100
e-mail: info@BioLineRx.com
|
Exhibit
Number
|
|
Exhibit Description
|
|
Method of Filing
|
|
|
|
|
|
|
Incorporated by reference to Exhibit 4.18 the Registrant’s Annual Report on Form 20-F (filed on March 10, 2016).
|
|||
|
|
|
|
|
|
Filed herewith.
|
|||
|
|
|
|
|
|
Filed herewith.
|
|||
|
|
|
|
|
|
Filed herewith.
|
|||
|
|
|
|
|
|
Filed herewith.
|
|||
|
|
|
|
|
|
Filed herewith.
|
(i) |
to include any prospectus required by Section 10(a)(3) of the Securities Act;
|
|
BIOLINERX LTD.
|
|
|
|
|
|
|
|
By:
|
/s/ Philip A. Serlin
|
|
|
|
Philip A. Serlin
|
|
|
|
Chief Executive Officer
|
|
SIGNATURE
|
|
TITLE
|
|
DATE
|
|
|
|
|
|
/s/ Philip A. Serlin
|
|
Chief Executive Officer,
|
|
December 29, 2023
|
Philip A. Serlin
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
/s/ Mali Zeevi
|
|
Chief Financial Officer
|
|
December 29, 2023
|
Mali Zeevi
|
|
(Principal Financial and Accounting Officer)
|
|
|
|
|
|
|
|
/s/ Aharon Schwartz
|
|
Chairman of the Board
|
|
December 29, 2023
|
Aharon Schwartz
|
|
|
|
|
|
|
|
|
|
/s/ Michael J. Anghel
|
|
Director
|
|
December 29, 2023
|
Michael J. Anghel
|
|
|
|
|
|
|
|
|
|
/s/ Rami Dar
|
|
Director
|
|
December 29, 2023
|
Rami Dar
|
|
|
|
|
|
|
|
|
|
/s/ B.J. Bormann
|
|
Director
|
|
December 29, 2023
|
B.J. Bormann
|
|
|
|
|
|
|
|
|
|
/s/ Raphael Hofstein
|
|
Director
|
|
December 29, 2023
|
Raphael Hofstein
|
|
|
|
|
|
|
|
|
|
s/ Avraham Molcho
|
|
Director
|
|
December 29, 2023
|
Avraham Molcho
|
|
|
|
|
|
|
|
|
|
/s/ Sandra Panem
|
|
Director
|
|
December 29, 2023
|
Sandra Panem
|
|
|
|
|
|
|
|
|
|
/s/ Shaoyu Yan
|
Director
|
December 29, 2023
|
||
Shaoyu Yan
|
/s/ Gal Cohen
|
|
Director
|
|
December 29, 2023
|
Gal Cohen
|
|
|
|
|
|
BioLineRx USA, Inc.
|
||
|
|
|
|
|
By:
|
/s/ Phil Serlin
|
|
|
|
Name: Phil Serlin
|
|
|
|
Title: Authorized Person
|
|
Tel. 972-3-69441111
|
|
Fax. 972-3-6091116
|
|
fbc@fbclawyers.com
|
|
Very truly yours,
/s/ FISCHER (FBC & Co.)
FISCHER (FBC & Co.)
|
Tel-Aviv, Israel
|
/s/ Kesselman & Kesselman
|
December 29, 2023
|
Certified Public Accountants (lsr.)
|
A member firm of PricewaterhouseCoopers International Limited
|
Security
Type
|
Security
Class
Title(1)
|
Fee
Calculation
Rule
|
Amount
Registered(2)
|
Proposed
Maximum
Offering
Price Per
Unit
|
Maximum
Aggregate
Offering
Price
|
Fee
Rate
|
Amount of
Registration
Fee
|
Equity
|
Ordinary Shares, par value NIS 0.10 per share (3)
|
Rule 457(c)
|
39,957,932
|
$0.0496
|
$1,981,913.43
|
0.00014760
|
$292.54
|
Equity
|
Ordinary Shares, par value NIS 0.10 per share (4)
|
Rule 457(c)
and Rule
457(h)
|
17,542,068
|
$0.106
|
$1,859,459.21
|
0.00014760
|
$274.46
|
Total Offering Amounts
|
$ 3,841,372.64
|
$567.00
|
|||||
Total Fee Offsets
|
— |
||||||
Net Fee Due
|
$567.00
|